ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - ADMA Biologics is a specialty producer of unique plasma-derived biologic products, primarily focusing on IVIG products that extract antibodies from human plasma [3] - The company has three FDA-approved commercial products and has preannounced total revenue of over $510 million for its commercial organization [3] Financial Performance - For the fourth quarter, ADMA expects revenue to exceed $139 million, with EBITDA projected at $77 million to $78 million or more, and net income anticipated to be around $50 million or more [3] - This financial performance represents a substantial increase compared to the third quarter of 2025 [3] Intellectual Property - The company holds intellectual property that protects its lead product ASCENIV until June 2035, focusing on the testing and identification processes [4]